Plus Therapeutics (CNSY) Stock Price, News & Analysis

Company Overview

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. The company’s lead investigational product is Rhenium-186 NanoLiposome, or 186RNL, a nanoliposome-based formulation designed to deliver the beta-emitting radioisotope rhenium-186 directly to tumor sites.

Plus Therapeutics is evaluating 186RNL in clinical programs for recurrent glioblastoma and leptomeningeal metastases, cancers that spread to the membranes surrounding the brain and spinal cord. The company’s approach is intended to provide localized radiation while limiting exposure to surrounding healthy tissue. These programs remain investigational and have not established the product as an approved commercial treatment.

Based in Austin, Texas, Plus Therapeutics serves the oncology market through research and clinical development activities conducted primarily in the United States. Marc Hedrick, M.D., has served as the company’s president and chief executive officer. The company has also pursued collaborations and government-supported development efforts related to its targeted radiotherapeutic platform.

Key Stats

• Today's Range: $1.86 to $1.96
• 50-Day Range: N/A
• 52-Week Range: $1.86 to $23.43
• Volume: 86,037 shs
• Average Volume: 75,820 shs
• Market Capitalization: $14.19 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Reduce

Plus Therapeutics Stock Analysis - MarketRank™

Plus Therapeutics scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Reduce

Consensus Rating

Plus Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Plus Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.7 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Plus Therapeutics are expected to grow in the coming year, from ($4.08) to ($2.84) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Plus Therapeutics is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Plus Therapeutics has a P/B Ratio of 2.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.81% of the float of Plus Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Plus Therapeutics has a short interest ratio ("days to cover") of 8.68.

Change versus previous month

Short interest in Plus Therapeutics has recently increased by 0.42%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Plus Therapeutics does not currently pay a dividend.

Dividend Growth

Plus Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: -0.60

News Sentiment

Plus Therapeutics has a news sentiment score of -0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Plus Therapeutics this week, compared to 3 articles on an average week.

Search Interest

Only 5 people have searched for CNSY on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.

MarketBeat Follows

2 people have added Plus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Plus Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.50% of the stock of Plus Therapeutics is held by insiders.

Percentage Held by Institutions

3.28% of the stock of Plus Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 9/24/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:CNSY
• CIK: 1095981
• Web: www.cerenome.com
• Phone: (737) 255-7194
• Fax: 858-450-4335
• Employees: 28
• Year Founded: 1996

Profitability

• EPS (Trailing Twelve Months): ($3.36)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$22.39 million
• Net Margins: -620.70%
• Pretax Margin: -620.70%
• Return on Equity: -394.17%
• Return on Assets: -151.36%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.37
• Quick Ratio: 0.65

Sales & Book Value

• Annual Sales: $5.21 million
• Price / Sales: 2.72
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.72 per share
• Price / Book: 2.60

Miscellaneous

• Outstanding Shares: 7,590,000
• Free Float: 7,400,000
• Market Cap: $14.19 million
• Optionable: N/A
• Beta: 1.39